Phase 1 clinical study of the acute and subacute safety and proof-of-concept efficacy of carbohydrate-derived fulvic acid

Justin John Gandy, Johanna Petronella Meeding, Jacques Ren&eacute; Snyman, Constance Elizabeth Jansen van RensburgDepartment of Pharmacology, Faculty of Health Sciences, University of Pretoria, Pretoria, South AfricaBackground: The purpose of this research was to determine the acute and suba...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Janse van Rensburg CE, Snyman JR, Meeding JP, Gandy JJ
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2012
Materias:	Therapeutics. Pharmacology RM1-950
Acceso en línea:	https://doaj.org/article/dbef94fa245540e6b9db725f69c32ea7
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:dbef94fa245540e6b9db725f69c32ea7
record_format	dspace
spelling	oai:doaj.org-article:dbef94fa245540e6b9db725f69c32ea72021-12-02T07:40:31ZPhase 1 clinical study of the acute and subacute safety and proof-of-concept efficacy of carbohydrate-derived fulvic acid1179-1438https://doaj.org/article/dbef94fa245540e6b9db725f69c32ea72012-02-01T00:00:00Zhttp://www.dovepress.com/phase-1-clinical-study-of-the-acute-and-subacute-safety-and-proof-of-c-a9296https://doaj.org/toc/1179-1438Justin John Gandy, Johanna Petronella Meeding, Jacques Ren&eacute; Snyman, Constance Elizabeth Jansen van RensburgDepartment of Pharmacology, Faculty of Health Sciences, University of Pretoria, Pretoria, South AfricaBackground: The purpose of this research was to determine the acute and subacute safety and proof-of-concept efficacy of carbohydrate-derived fulvic acid (CHD-FA).Methods: In this double-blind study, 30 male volunteers with predetermined atopy were randomly assigned to either Group A or Group B, each consisting of 15 participants. In part 1 of the study, the groups were administered increasing amounts of CHD-FA, ranging from 5 mL to 40 mL, provided that no adverse events had occurred at the previous dosage. In part 2, Group A participants received 20 mL of 3.8% CHD-FA twice daily for 3 days and were monitored for a week. Because no adverse events occurred, Group B received 40 mL of 3.8% CHD-FA twice daily for a period of 3 days. In part 3, both groups received either 40 mL of 3.8% CHD-FA or placebo twice daily for a period of one week, followed by a one-week washout period before crossover to the alternative treatment schedule. Parameters used to establish safety were electrocardiography, a physical examination, a health questionnaire, and hematology and biochemistry, determined at baseline, during regular calculated intervals, and at the end of each part of the study. A skin prick test was done as part of the screening process and, from the result, the allergen the participant was most allergic to was then selected, along with the positive histamine and negative control to be repeated at the start and end of each respective stage.Results: Safety parameters remained constant throughout the trial. A significant decrease in skin prick test results was observed.Conclusion: No severe adverse events occurred, establishing that CHD-FA to be safe at doses up to 40 mL twice daily for a week and that at this dosage CHD-FA acts as an anti-inflammatory agent. These findings confirm earlier animal data.Keywords: CHD-FA, safety, efficacy, anti-inflammatoryJanse van Rensburg CESnyman JRMeeding JPGandy JJDove Medical PressarticleTherapeutics. PharmacologyRM1-950ENClinical Pharmacology: Advances and Applications, Vol 2012, Iss default, Pp 7-11 (2012)
institution	DOAJ
collection	DOAJ
language	EN
topic	Therapeutics. Pharmacology RM1-950
spellingShingle	Therapeutics. Pharmacology RM1-950 Janse van Rensburg CE Snyman JR Meeding JP Gandy JJ Phase 1 clinical study of the acute and subacute safety and proof-of-concept efficacy of carbohydrate-derived fulvic acid
description	Justin John Gandy, Johanna Petronella Meeding, Jacques Ren&eacute; Snyman, Constance Elizabeth Jansen van RensburgDepartment of Pharmacology, Faculty of Health Sciences, University of Pretoria, Pretoria, South AfricaBackground: The purpose of this research was to determine the acute and subacute safety and proof-of-concept efficacy of carbohydrate-derived fulvic acid (CHD-FA).Methods: In this double-blind study, 30 male volunteers with predetermined atopy were randomly assigned to either Group A or Group B, each consisting of 15 participants. In part 1 of the study, the groups were administered increasing amounts of CHD-FA, ranging from 5 mL to 40 mL, provided that no adverse events had occurred at the previous dosage. In part 2, Group A participants received 20 mL of 3.8% CHD-FA twice daily for 3 days and were monitored for a week. Because no adverse events occurred, Group B received 40 mL of 3.8% CHD-FA twice daily for a period of 3 days. In part 3, both groups received either 40 mL of 3.8% CHD-FA or placebo twice daily for a period of one week, followed by a one-week washout period before crossover to the alternative treatment schedule. Parameters used to establish safety were electrocardiography, a physical examination, a health questionnaire, and hematology and biochemistry, determined at baseline, during regular calculated intervals, and at the end of each part of the study. A skin prick test was done as part of the screening process and, from the result, the allergen the participant was most allergic to was then selected, along with the positive histamine and negative control to be repeated at the start and end of each respective stage.Results: Safety parameters remained constant throughout the trial. A significant decrease in skin prick test results was observed.Conclusion: No severe adverse events occurred, establishing that CHD-FA to be safe at doses up to 40 mL twice daily for a week and that at this dosage CHD-FA acts as an anti-inflammatory agent. These findings confirm earlier animal data.Keywords: CHD-FA, safety, efficacy, anti-inflammatory
format	article
author	Janse van Rensburg CE Snyman JR Meeding JP Gandy JJ
author_facet	Janse van Rensburg CE Snyman JR Meeding JP Gandy JJ
author_sort	Janse van Rensburg CE
title	Phase 1 clinical study of the acute and subacute safety and proof-of-concept efficacy of carbohydrate-derived fulvic acid
title_short	Phase 1 clinical study of the acute and subacute safety and proof-of-concept efficacy of carbohydrate-derived fulvic acid
title_full	Phase 1 clinical study of the acute and subacute safety and proof-of-concept efficacy of carbohydrate-derived fulvic acid
title_fullStr	Phase 1 clinical study of the acute and subacute safety and proof-of-concept efficacy of carbohydrate-derived fulvic acid
title_full_unstemmed	Phase 1 clinical study of the acute and subacute safety and proof-of-concept efficacy of carbohydrate-derived fulvic acid
title_sort	phase 1 clinical study of the acute and subacute safety and proof-of-concept efficacy of carbohydrate-derived fulvic acid
publisher	Dove Medical Press
publishDate	2012
url	https://doaj.org/article/dbef94fa245540e6b9db725f69c32ea7
work_keys_str_mv	AT jansevanrensburgce phase1clinicalstudyoftheacuteandsubacutesafetyandproofofconceptefficacyofcarbohydratederivedfulvicacid AT snymanjr phase1clinicalstudyoftheacuteandsubacutesafetyandproofofconceptefficacyofcarbohydratederivedfulvicacid AT meedingjp phase1clinicalstudyoftheacuteandsubacutesafetyandproofofconceptefficacyofcarbohydratederivedfulvicacid AT gandyjj phase1clinicalstudyoftheacuteandsubacutesafetyandproofofconceptefficacyofcarbohydratederivedfulvicacid
_version_	1718399309569851392

Phase 1 clinical study of the acute and subacute safety and proof-of-concept efficacy of carbohydrate-derived fulvic acid

Ejemplares similares